Combination kills cancer

New York - Results from the largest-ever phase III trial in advanced metastatic melanoma, while preliminary, suggest dacarbazine (DTIC) plus an investigational antisense compound (oblimersen sodium, or Genasense) may significantly improve overall survival versus DTIC alone, according to Anna C. Pavlick, D.O.

Related Videos
Related Content

How to Educate Patients on Sun Protection

May 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial Goals

May 26th 2023

The Mainstream Patient: May 26

May 26th 2023

How to Educate Patients on Sun Protection

May 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial Goals

May 26th 2023

The Mainstream Patient: May 26

May 26th 2023

How to Educate Patients on Sun Protection

May 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis

May 26th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dealing With Student Loan Debt: How to Budget for Repayment and Other Financial Goals

May 26th 2023

The Mainstream Patient: May 26

May 26th 2023
© 2023 MJH Life Sciences

All rights reserved.